Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$1.76 - $4.94 $660 - $1,852
-375 Reduced 3.21%
11,295 $22,000
Q2 2022

Aug 15, 2022

SELL
$2.47 - $6.77 $164,420 - $450,658
-66,567 Reduced 85.08%
11,670 $44,000
Q1 2022

May 11, 2022

BUY
$5.22 - $11.86 $10,789 - $24,514
2,067 Added 2.71%
78,237 $510,000
Q4 2021

Feb 11, 2022

BUY
$11.43 - $19.2 $27,717 - $46,560
2,425 Added 3.29%
76,170 $887,000
Q3 2021

Nov 12, 2021

BUY
$15.82 - $21.57 $270,094 - $368,264
17,073 Added 30.13%
73,745 $1.37 Million
Q2 2021

Aug 11, 2021

BUY
$19.29 - $26.38 $573,684 - $784,541
29,740 Added 110.43%
56,672 $1.2 Million
Q1 2021

May 13, 2021

SELL
$20.3 - $31.75 $974 - $1,524
-48 Reduced 0.18%
26,932 $546,000
Q4 2020

Feb 09, 2021

BUY
$19.14 - $28.13 $516,397 - $758,947
26,980 New
26,980 $716,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $85.1M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.